GIP and obesity disorder: Tirzepatide (Mounjaro®), a dual glucose-dependent insulinotropic peptide/glucagon-like peptide 1 (GIP/GLP1) receptor agonist, was recently approved for diabetes management as well as weight reduction for nondiabetic individuals with obesity or overweight and weight-related health problems.